pyrroles has been researched along with Cancer of the Urinary Tract in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Hawary, M; Bylow, KA; Daignault, S; Dreicer, R; Grivas, PD; Hussain, M; Keller, ET; Kohli, M; Nanus, DM; Petrylak, DP; Smith, DC; Sottnik, JL; Stadler, WM; Tagawa, ST; Vaughn, DJ; Wong, SG | 1 |
| Barber, J; Casbard, A; Chester, J; Cowles, R; Crabb, S; Elliott, T; Evans, J; Geldart, T; Griffiths, G; Huddart, RA; Jones, RJ; Mead, G; Protheroe, A; Smith, J | 1 |
| Birtle, A | 1 |
| Chang, SS | 1 |
| Fujisawa, M; Miyake, H | 1 |
| Aguilar, G; Albanell, J; Bellmunt, J; Calvo, A; Carles, J; Castellano, D; Gallardo, E; González-Larriba, JL; Maroto, P; Mellado, B; Perez-Gracia, JL; Prior, C; Villanueva, X | 1 |
| Al-Ahmadie, H; Bajorin, DF; Flaherty, AM; Gallagher, DJ; Garcia-Grossman, I; Gerst, SR; Gounder, SK; Milowsky, MI; Ostrovnaya, I; Regazzi, A; Riches, J; Trout, A | 1 |
1 review(s) available for pyrroles and Cancer of the Urinary Tract
| Article | Year |
|---|---|
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms | 2010 |
3 trial(s) available for pyrroles and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Transitional Cell; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Sample Size; Sunitinib; Treatment Outcome; Urologic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Urologic Neoplasms | 2015 |
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Contrast Media; Disease-Free Survival; Female; Humans; Indoles; Interleukin-8; Kaplan-Meier Estimate; Male; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Urologic Neoplasms | 2011 |
3 other study(ies) available for pyrroles and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Heir to the throne or young pretender: can targeted therapy added to gemcitabine-cisplatin doublet therapy improve outcomes for advanced urothelial cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Deoxycytidine; Female; Humans; Indoles; Male; Pyrroles; Urologic Neoplasms | 2015 |
Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Deoxycytidine; Female; Humans; Indoles; Male; Pyrroles; Urologic Neoplasms | 2015 |
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Pressure; Carcinoma, Transitional Cell; Cell Cycle Proteins; Drug Administration Schedule; Humans; Hypertension; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Logistic Models; New York City; Phosphoproteins; Phosphorylation; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Tissue Array Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Urologic Neoplasms; Urothelium; Vascular Endothelial Growth Factor Receptor-2 | 2011 |